CYXO — Cyxone AB Share News
0.000.00%
Last trade - 00:00- SEK14.25m
- SEK8.44m
Advisory: Multiple dated alerts withdrawn
Brief: Cyxone To Apply For Listing On Stockholm Main Market
Brief: Cyxone Gets Approval To Start Phase 2 Study With Rabeximod In COVID-19 Patients
Brief: Cyxone Q3 Loss After Financial Items Narrows To KSEK 12 608
Brief: Cyxone Says Carried Out Directed Issue Of 4,075,000 Units At Subscription Price Of SEK 4.70 Per Unit
Brief: Cyxone Intends To Carry Out A Directed Issue Of Units Of Approx. SEK 19 Mln
Brief: Cyxone Files Patent Application To Extend Exclusivity Of Rabeximod
Brief: Cyxone Announces Positive Results From Regulatory Toxicology Studies Of Rabeximod
Brief: Cyxone Gets SEK 21.8 Mln In Proceeds From Fully Utilized Investment Option Agreement
Brief: Cyxone Revises Development Plan For Rabeximod
Brief: Cyxone Raises SEK 1 Mln In A Second Directed Share Issue
Brief: Cyxone Plans To Initiate A Phase 2 Clinical Trial With Rabeximod In COVID-19 Patients
Brief: Cyxone Q2 Loss After Financial Items Widens To SEK 14.2 Mln
Brief: Cyxone Raises SEK 0.9 Million In Directed Issue
Brief: Cyxone Enters Development Agreement With Inventor Kalev Kask
Brief: Cyxone Files New Patent Applications Following Additional Innovation Achievements
Brief: Tara Heitner Appointed New CEO For Cyxone
Brief: Cyxone Q1 Pre-Tax Loss Widens To SEK 10.2 Million
Brief: Cyxone: Medical University Of Vienna Fils New Patent Application For Extended Protection Of T20K